Synlogic Inc (NASDAQ:SYBX)

1.08
Delayed Data
As of May 27
 -0.01 / -0.92%
Today’s Change
1.02
Today|||52-Week Range
4.54
-55.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$92.7M

Company Description

Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Contact Information

Synlogic, Inc.
301 Binney Street
Cambridge Massachusetts 02142
P:(617) 401-9975
Investor Relations:

Employees

Shareholders

Other institutional24.59%
Individual stakeholders20.08%
Mutual fund holders17.20%

Top Executives

Aoife M. BrennanPresident, Chief Executive Officer & Director
Antoine AwadChief Operating Officer
Michael JensenChief Financial Officer
David L. HavaChief Scientific Officer
Jamie AustinVice President & Head-Regulatory Affairs